Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

This is a multicenter, single-arm phase II clinical study to evaluate the safety and efficacy of pyrotinib maleate as a first-line treatment for HER2-mutated or amplified non-small cell lung cancer. Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.

Trial Details

NCT ID

NCT05751018

Phase

PHASE2

Sponsor

Peking Union Medical College Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Pyrotinib

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

1\. Age: ≥18 years old; 2. Histologically confirmed stage IIIB or IV non-small cell lung cancer; 3. Have not previously received systemic anticance…
Neutrophil count (ANC) ≥ 1,500/mm3 (1.5×109/L);
Platelet count (PLT) ≥ 75,000/mm3 (75×109/L);
Hemoglobin (Hb) ≥ 8 g/dL (80 g/L);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →